Skip to main content
Erschienen in:

01.06.2007 | Leitthema

Ganzkörperbestrahlung

Rolle und Indikationsspektrum

verfasst von: F. Heinzelmann, C. Faul, Prof. Dr. C. Belka

Erschienen in: Die Onkologie | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch die Entwicklung von Hochdosiskonzepten mit nachfolgender Blutstammzelltransplantation konnte eine Kuration ansonsten letal verlaufender Erkrankungen des hämatopoetischen Systems erreicht werden. Bereits bei den initialen Behandlungskonzepten war die Ganzkörperkörperbestrahlung ein essenzieller Therapiebestandteil der Konditionierung vor allogener Transplantation. Das Indikationsspektrum umfasst v. a. akute Leukämien, chronisch-myeloische Leukämie, myelodysplastisches Syndrom und Non-Hodgkin-Lymphome. Die bisher durchgeführten Hochdosiskonzepte wurden in den vergangenen Jahren aufgrund der hohen Toxizität zunehmend durch dosisreduzierte Konzepte (RIC) ersetzt, die v. a. bei älteren Patienten bzw. bei Patienten mit Komorbiditäten zum Einsatz kommen. Der Stellenwert der verschiedenen RIC-Protokolle mit und ohne Beteiligung der Ganzkörperbestrahlung sowie das exakte Indikationsspektrum sind noch weitgehend unklar.
Literatur
1.
Zurück zum Zitat Thomas ED, Epstein RB (1965) Bone marrow transplantation in acute leukemia. Cancer Res 25: 1521–1524PubMed Thomas ED, Epstein RB (1965) Bone marrow transplantation in acute leukemia. Cancer Res 25: 1521–1524PubMed
2.
Zurück zum Zitat Wheldon TE (1997) The radiobiological basis of total body irradiation. Br J Radiol 70: 1204–1207PubMed Wheldon TE (1997) The radiobiological basis of total body irradiation. Br J Radiol 70: 1204–1207PubMed
3.
Zurück zum Zitat Wheldon TE, Barrett A (2001) Radiobiological modelling of the treatment of leukaemia by total body irradiation. Radiother Oncol 58: 227–233PubMedCrossRef Wheldon TE, Barrett A (2001) Radiobiological modelling of the treatment of leukaemia by total body irradiation. Radiother Oncol 58: 227–233PubMedCrossRef
4.
Zurück zum Zitat Champlin RE, Horowitz MM, van Bekkum DW et al. (1989) Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 73: 606–613PubMed Champlin RE, Horowitz MM, van Bekkum DW et al. (1989) Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 73: 606–613PubMed
5.
Zurück zum Zitat Blaise D, Maraninchi D, Archimbaud, Reiffers E et al. (1992) Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 79: 2578–2582PubMed Blaise D, Maraninchi D, Archimbaud, Reiffers E et al. (1992) Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 79: 2578–2582PubMed
6.
Zurück zum Zitat Blaise D, Maraninchi D, Michallet M et al. (2001) Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 97: 3669–3671PubMedCrossRef Blaise D, Maraninchi D, Michallet M et al. (2001) Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 97: 3669–3671PubMedCrossRef
7.
Zurück zum Zitat Ringden O, Ruutu T, Remberger M et al. (1994) A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83: 2723–2730PubMed Ringden O, Ruutu T, Remberger M et al. (1994) A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83: 2723–2730PubMed
8.
Zurück zum Zitat Ringden O, Remberger M, Ruutu T, Nikoskelainen et al. (1999) Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 93: 2196–2201PubMed Ringden O, Remberger M, Ruutu T, Nikoskelainen et al. (1999) Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 93: 2196–2201PubMed
9.
Zurück zum Zitat Devergie A, Blaise D, Attal M et al. (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85: 2263–2268PubMed Devergie A, Blaise D, Attal M et al. (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85: 2263–2268PubMed
10.
Zurück zum Zitat Socie G, Clift RA, Blaise D et al. (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98: 3569–3574PubMedCrossRef Socie G, Clift RA, Blaise D et al. (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98: 3569–3574PubMedCrossRef
11.
Zurück zum Zitat Clift RA, Buckner CD, Thomas ED et al. (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84: 2036–2043PubMed Clift RA, Buckner CD, Thomas ED et al. (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84: 2036–2043PubMed
12.
Zurück zum Zitat Clift RA, Radich J, Appelbaum FR et al. (1999) Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94: 3960–3962PubMed Clift RA, Radich J, Appelbaum FR et al. (1999) Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94: 3960–3962PubMed
13.
Zurück zum Zitat Slattery JT, Sanders JE, Buckner CD et al. (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16: 31–42PubMed Slattery JT, Sanders JE, Buckner CD et al. (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16: 31–42PubMed
14.
Zurück zum Zitat Slattery JT, Clift RA, Buckner CD et al. (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89: 3055–3060PubMed Slattery JT, Clift RA, Buckner CD et al. (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89: 3055–3060PubMed
15.
Zurück zum Zitat Radich JP, Gooley T, Bensinger W et al. (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102: 31–35PubMedCrossRef Radich JP, Gooley T, Bensinger W et al. (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102: 31–35PubMedCrossRef
16.
Zurück zum Zitat Davies SM, Ramsay NK, Klein JP et al. (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18: 340–347PubMed Davies SM, Ramsay NK, Klein JP et al. (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18: 340–347PubMed
17.
Zurück zum Zitat Granados E, de La Camara R, Madero L et al. (2000) Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 85: 1060–1067PubMed Granados E, de La Camara R, Madero L et al. (2000) Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 85: 1060–1067PubMed
18.
Zurück zum Zitat Copelan EA, Deeg HJ (1992) Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 80: 1648–1658PubMed Copelan EA, Deeg HJ (1992) Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 80: 1648–1658PubMed
19.
Zurück zum Zitat Blume KG, Kopecky KJ, Henslee-Downey JP et al. (1993) A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 81: 2187–2193PubMed Blume KG, Kopecky KJ, Henslee-Downey JP et al. (1993) A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 81: 2187–2193PubMed
20.
Zurück zum Zitat Hartman AR, Williams SF, Dillon JJ (1998) Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 22: 439–443PubMedCrossRef Hartman AR, Williams SF, Dillon JJ (1998) Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 22: 439–443PubMedCrossRef
21.
Zurück zum Zitat Heinzelmann F, Ottinger H, Muller CH et al. (2006) Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol 182: 222–230PubMedCrossRef Heinzelmann F, Ottinger H, Muller CH et al. (2006) Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol 182: 222–230PubMedCrossRef
22.
Zurück zum Zitat Quast U (1987) Total body irradiation--review of treatment techniques in Europe. Radiother Oncol 9: 91–106PubMedCrossRef Quast U (1987) Total body irradiation--review of treatment techniques in Europe. Radiother Oncol 9: 91–106PubMedCrossRef
23.
Zurück zum Zitat Van Dyk J (1983) Magna-field irradiation: physical considerations. Int J Radiat Oncol Biol Phys 9: 1913–1918PubMed Van Dyk J (1983) Magna-field irradiation: physical considerations. Int J Radiat Oncol Biol Phys 9: 1913–1918PubMed
24.
Zurück zum Zitat Deeg HJ, Sullivan KM, Buckner CD et al. (1986) Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1: 151–157PubMed Deeg HJ, Sullivan KM, Buckner CD et al. (1986) Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1: 151–157PubMed
25.
Zurück zum Zitat Girinsky T, Benhamou E, Bourhis JH, Dhermain F et al. (2000) Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 18: 981–986PubMed Girinsky T, Benhamou E, Bourhis JH, Dhermain F et al. (2000) Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 18: 981–986PubMed
26.
Zurück zum Zitat Clift RA, Buckner CD, Appelbaum FR et al. (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76: 1867–1871PubMed Clift RA, Buckner CD, Appelbaum FR et al. (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76: 1867–1871PubMed
27.
Zurück zum Zitat Clift RA, Buckner CD, Appelbaum FR et al. (1991) Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77: 1660–1665PubMed Clift RA, Buckner CD, Appelbaum FR et al. (1991) Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77: 1660–1665PubMed
28.
Zurück zum Zitat Bieri S, Helg C, Chapuis B et al. (2001) Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 49: 1071–1077PubMedCrossRef Bieri S, Helg C, Chapuis B et al. (2001) Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 49: 1071–1077PubMedCrossRef
29.
Zurück zum Zitat Mah K, Van Dyk J, Keane T et al. (1987) Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 13: 179–188PubMed Mah K, Van Dyk J, Keane T et al. (1987) Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 13: 179–188PubMed
30.
Zurück zum Zitat Boulad F, Bromley M, Black P et al. (1995) Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant 15: 71–76PubMed Boulad F, Bromley M, Black P et al. (1995) Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant 15: 71–76PubMed
31.
Zurück zum Zitat Thomas O, Mahe M, Campion L et al. (2001) Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 49: 125–131PubMedCrossRef Thomas O, Mahe M, Campion L et al. (2001) Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 49: 125–131PubMedCrossRef
32.
Zurück zum Zitat Sanders JE, Hawley J, Levy W et al. (1996) Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 87: 3045–3052PubMed Sanders JE, Hawley J, Levy W et al. (1996) Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 87: 3045–3052PubMed
33.
Zurück zum Zitat Miralbell R, Bieri S, Mermillod B et al. (1996) Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 14: 579–585PubMed Miralbell R, Bieri S, Mermillod B et al. (1996) Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 14: 579–585PubMed
34.
Zurück zum Zitat Hamon MD, Gale RF, Macdonald ID et al. (1993) Incidence of cataracts after single fraction total body irradiation: the role of steroids and graft versus host disease. Bone Marrow Transplant 12: 233–236PubMed Hamon MD, Gale RF, Macdonald ID et al. (1993) Incidence of cataracts after single fraction total body irradiation: the role of steroids and graft versus host disease. Bone Marrow Transplant 12: 233–236PubMed
35.
Zurück zum Zitat van Kempen-Harteveld ML, Struikmans H, Kal HB et al. (2000) Cataract-free interval and severity of cataract after total body irradiation and bone marrow transplantation: influence of treatment parameters. Int J Radiat Oncol Biol Phys 48: 807–815CrossRef van Kempen-Harteveld ML, Struikmans H, Kal HB et al. (2000) Cataract-free interval and severity of cataract after total body irradiation and bone marrow transplantation: influence of treatment parameters. Int J Radiat Oncol Biol Phys 48: 807–815CrossRef
36.
Zurück zum Zitat Benyunes MC, Sullivan KM, Deeg HJ et al. (1995) Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys 32: 661–670PubMedCrossRef Benyunes MC, Sullivan KM, Deeg HJ et al. (1995) Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys 32: 661–670PubMedCrossRef
37.
Zurück zum Zitat Belkacemi Y, Labopin M, Vernant JP et al. (1998) Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 41: 659–668PubMedCrossRef Belkacemi Y, Labopin M, Vernant JP et al. (1998) Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 41: 659–668PubMedCrossRef
38.
Zurück zum Zitat Peper M, Steinvorth S, Schraube P et al. (2000) Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors. Int J Radiat Oncol Biol Phys 46: 303–311PubMedCrossRef Peper M, Steinvorth S, Schraube P et al. (2000) Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors. Int J Radiat Oncol Biol Phys 46: 303–311PubMedCrossRef
39.
Zurück zum Zitat Wenz F, Steinvorth S, Lohr F et al. (2000) Prospective evaluation of delayed central nervous system (CNS) toxicity of hyperfractionated total body irradiation (TBI). Int J Radiat Oncol Biol Phys 48: 1497–1501PubMedCrossRef Wenz F, Steinvorth S, Lohr F et al. (2000) Prospective evaluation of delayed central nervous system (CNS) toxicity of hyperfractionated total body irradiation (TBI). Int J Radiat Oncol Biol Phys 48: 1497–1501PubMedCrossRef
40.
Zurück zum Zitat Curtis RE, Rowlings PA, Deeg HJ et al. (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336: 897–904PubMedCrossRef Curtis RE, Rowlings PA, Deeg HJ et al. (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336: 897–904PubMedCrossRef
41.
Zurück zum Zitat Socie G, Curtis RE, Deeg HJ et al. (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18: 348–357PubMed Socie G, Curtis RE, Deeg HJ et al. (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18: 348–357PubMed
42.
Zurück zum Zitat Storb R, Yu C, Wagner JL et al. (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89: 3048–3054PubMed Storb R, Yu C, Wagner JL et al. (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89: 3048–3054PubMed
43.
Zurück zum Zitat Stewart FM, Zhong S, Wuu J et al. (1998) Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 91: 3681–3687PubMed Stewart FM, Zhong S, Wuu J et al. (1998) Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 91: 3681–3687PubMed
44.
Zurück zum Zitat Luznik L, Jalla S, Engstrom LW et al. (2001) Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98: 3456–3464PubMedCrossRef Luznik L, Jalla S, Engstrom LW et al. (2001) Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98: 3456–3464PubMedCrossRef
45.
Zurück zum Zitat McSweeney PA, Niederwieser D, Shizuru JA et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390–3400PubMedCrossRef McSweeney PA, Niederwieser D, Shizuru JA et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390–3400PubMedCrossRef
46.
Zurück zum Zitat Ballen KK, Becker PS, Emmons RV et al. (2002) Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100: 442–450PubMedCrossRef Ballen KK, Becker PS, Emmons RV et al. (2002) Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100: 442–450PubMedCrossRef
47.
Zurück zum Zitat Or R, Shapira MY, Resnick I et al. (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101: 441–445PubMedCrossRef Or R, Shapira MY, Resnick I et al. (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101: 441–445PubMedCrossRef
48.
Zurück zum Zitat Slavin S, Nagler A, Naparstek E, Kapelushnik et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756–763PubMed Slavin S, Nagler A, Naparstek E, Kapelushnik et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756–763PubMed
49.
Zurück zum Zitat Gerull S, Goerner M, Benner A et al. (2005) Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 36: 963–969PubMedCrossRef Gerull S, Goerner M, Benner A et al. (2005) Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 36: 963–969PubMedCrossRef
50.
Zurück zum Zitat Niederwieser D, Maris M, Shizuru JA et al. (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable coimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620–1629PubMedCrossRef Niederwieser D, Maris M, Shizuru JA et al. (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable coimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620–1629PubMedCrossRef
51.
Zurück zum Zitat Kroger N, Zabelina T, Schieder H et al. (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128: 690–697PubMedCrossRef Kroger N, Zabelina T, Schieder H et al. (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128: 690–697PubMedCrossRef
52.
Zurück zum Zitat Khoury H, Adkins D, Brown R et al. (2001) Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. Biol Blood Marrow Transplant 7: 352–358PubMedCrossRef Khoury H, Adkins D, Brown R et al. (2001) Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. Biol Blood Marrow Transplant 7: 352–358PubMedCrossRef
53.
Zurück zum Zitat Hegenbart U, Niederwieser D, Sandmaier BM et al. (2006) Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24: 444–453PubMedCrossRef Hegenbart U, Niederwieser D, Sandmaier BM et al. (2006) Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24: 444–453PubMedCrossRef
54.
Zurück zum Zitat Kroger N, Bornhauser M, Ehninger G et al. (2003) Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82: 336–342PubMedCrossRef Kroger N, Bornhauser M, Ehninger G et al. (2003) Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82: 336–342PubMedCrossRef
55.
Zurück zum Zitat Wong R, Giralt SA, Martin T et al. (2003) Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102: 3052–3059PubMedCrossRef Wong R, Giralt SA, Martin T et al. (2003) Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102: 3052–3059PubMedCrossRef
56.
Zurück zum Zitat Bertz H, Potthoff K, Finke J (2003) Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21: 1480–1484PubMedCrossRef Bertz H, Potthoff K, Finke J (2003) Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21: 1480–1484PubMedCrossRef
57.
Zurück zum Zitat Sayer HG, Kroger M, Beyer J et al. (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31: 1089–1095PubMedCrossRef Sayer HG, Kroger M, Beyer J et al. (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31: 1089–1095PubMedCrossRef
58.
Zurück zum Zitat Nagler A, Slavin S, Varadi G et al. (2000) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25: 1021–1028PubMedCrossRef Nagler A, Slavin S, Varadi G et al. (2000) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25: 1021–1028PubMedCrossRef
59.
Zurück zum Zitat Aoudjhane M, Labopin M, Gorin NC et al. (2005) Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19: 2304–2312PubMedCrossRef Aoudjhane M, Labopin M, Gorin NC et al. (2005) Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19: 2304–2312PubMedCrossRef
Metadaten
Titel
Ganzkörperbestrahlung
Rolle und Indikationsspektrum
verfasst von
F. Heinzelmann
C. Faul
Prof. Dr. C. Belka
Publikationsdatum
01.06.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1089-4

Weitere Artikel der Ausgabe 5/2007

Der Onkologe 5/2007 Zur Ausgabe

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.